Biomarcadores moleculares y celulares. Implicaciones en la terapia dirigida

  1. Casado, D. 1
  2. Bellido, L. 1
  3. Del Barco, E. 1
  4. Cigarral, B. 1
  5. Escalera, E. 1
  6. Claros, J. 1
  7. Barrios, B. 1
  8. Figuero, L. 1
  9. Olivares, A. 1
  10. López, A. 1
  11. Terán, E. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1418-1423

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.008 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Alrededor de un 20% de los pacientes con adenocarcinoma de pulmón metastásico van a tener una mutación accionable que puede ser tratada con una terapia dirigida. Los tratamientos con inhibidor de la tirosina quinasa (ITK) tanto de EGFR como ALK y ROS-1 han demostrado beneficio clínico en aquellos pacientes con dicha mutación, mayor que con tratamientos de quimioterapia. Por ello, es imprescindible estudiar estas alteraciones moleculares antes de comenzar el tratamiento antineoplásico. Existen varios ITK de distintas generaciones con diferentes grados de eficacia. Conocer los mecanismos de resistencia a estas terapias también es necesario para mejorar dichos tratamientos. Determinar otras mutaciones menos frecuentes puede suponer una opción terapéutica en pacientes que puedan recibir el tratamiento dirigido.

Referencias bibliográficas

  • Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol [Internet]. 2013;8(7):823-59. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23552377/
  • Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol [Inter-net]. 2014;25(9):1681-90. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24718890/
  • Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of American pathologists/ international association for the study of lung cancer/ association for molecular pathology clinical practice guideline update. J Clin Oncol [Internet]. 2018;36(9):911-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29401004/
  • Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol [Internet]. 2014 Feb ;15(2):213-22. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24439929/
  • Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewas-kulyong B, Lee KH, et al. Osimertinib in Untreated EGFR -mutated advanced non–small-cell lung cancer. N Engl J Med [Internet]. 2018 Jan 11;378(2):113-25. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1713137
  • Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med [Internet]. 2017 May 1;5(5):435-44. Disponible en: https://pub-med.ncbi.nlm.nih.gov/28408243/
  • Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-muta-ted, advanced non-small-cell lung cancer (RELAY): a randomised, dou-ble-blind, placebo-controlled, phase 3 trial. Lancet Oncol [Internet]. 2019 Dec 1;20(12):1655-69. Disponible en: http://www.thelancet.com/article/S1470204519306345/fulltext
  • Nakamura A, Inoue A, Morita S, Hosomi Y, Kato T, Fukuhara T, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol. 2018;36(15)Suppl:9005.
  • Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study. JAMA Oncol [Internet]. 2016 Mar 1; 2(3):305-12. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26720423/
  • Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Rama-lingam SS, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536-1544. doi10.1016/j.annonc.2020.08.2100.
  • Mok T, Ahn M-J, Han J-Y, Kang JH, Katakami N, Kim H, et al. CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). J Clin Oncol. 2017;35(15)Suppl:9005.
  • Kerr KM, López-Ríos F. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 2016;27 Suppl 3:iii16-iii24.doi: 10.1093/annonc/mdw302.
  • Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. 2017 Aug 31;377(9):829-38. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1704795
  • Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alecti-nib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet [Inter-net]. 2017 Jul 1;390(10089):29-39. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28501140/
  • Camidge DR, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Lee J-S, et al. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. 2018 Nov 22;379(21):2027-39. Disponible en: http://www.nejm.org/doi/10.1056/ NEJMoa1810171
  • Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, et al. Alectinib versus crizotinib in untreated Asian patients with ana-plastic lymphoma kinase-positive non-small-cell lung cancer (ALE-SIA): a randomised phase 3 study. Lancet Respir Med [Internet]. 2019 May 1;7(5):437-46. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30981696/
  • Deeb KK, Hohman CM, Risch NF, Metzger DJ, Starostik P. Routine clinical mutation profiling of non-small cell lung cancer using next-gene-ration sequencing. Arch Pathol Lab Med [Internet]. 2015 Jul 1;139(7):913-21. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26125431/
  • Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-re-arranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet [Internet]. 2017;389(10072):917-29. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28126333/
  • CNS efficacy results from the phase III ALUR study of alectinib vs che-motherapy in previously treated ALK+ NSCLC | OncologyPRO [Inter-net].Disponible en: https://oncologypro.esmo.org/meeting-resources/esmo-2017-congress/CNS-efficacy-results-from-the-phase-III-ALUR-study-of-alectinib-vs-chemotherapy-in-pre-viously-treated-ALK-NSCLC
  • Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma ki-nase-positive non-small-cell lung cancer: A randomized, multicenter pha-se II trial. J Clin Oncol [Internet]. 2017 Aug 1;35(22):2490-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/ 28475456/
  • Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lym-phoma kinase-positive non–small-cell lung cancer. J Clin Oncol [Inter-net]. 2019;37(16):1370-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30892989/
  • Yang Y, Zhou J, Zhou J, Feng J, Zhuang W, Chen J, et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respir Med [Internet]. 2020 Jan 1 [consultado 29 Sep 2020];8(1):45-53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31628085/
  • Mazières J, Rouvière D, D.Milia J, Filleron T, Zalcman G, Biondani P, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 earrangement: Results from the EUROS1 cohort. J Clin Oncol [Inter-net]. 2015 Mar 20;33(9):992-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25667280/
  • Cho BC, Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, et al. Open-label, multicenter, phase II Study of ceritinib in patients with non–small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol [Internet]. 2017 Aug 10;35(23):2613-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28520527/
  • Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integra-ted analysis of three phase 1–2 trials. Lancet Oncol [Internet]. 2020 Feb 1;21(2):261-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31838015/
  • Drilon A, Ou SHI, Cho BC, Kim DW, Lee J, Lin JJ, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that po-tently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov. 2018;8(10):1227-36.
  • Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Dabrafenib plus trametinib in patients with previously untreated BRA-FV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol [Internet]. 2017 Oct 1;18(10):1307-16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/ 28919011/
  • Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol [Inter-net]. 2019 Jul 1;72(7):460-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31072837/
  • Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-47.
  • Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, et al. Targe-ting her2 with trastuzumab deruxtecan: A dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov [Internet]. 2020 May 1;10(5):688-701. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32213540/
  • Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature [Internet]. 2019 Nov 7;575(7781):217-23. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31666701/
  • Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med [Internet]. 2018 Feb 22;378(8):731-9. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa1714448
  • Goto K, Oxnard GR, Tan DS-W, Loong HHF, Bauer TM, Gainor JF, et al. Selpercatinib (LOXO-292) in patients with RET- fusion+ non-small cell lung cancer. J Clin Oncol. 2020 May 20;38(15)Suppl:3584.
  • Drilon AE, Camidge DR, Ou S-HI, Clark JW, Socinski MA, Weiss J, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol. 2016 May 20;34(15)Suppl:108.
  • Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepoti-nib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med [Internet]. 2020 Sep 3;383(10):931-43. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32469185/
  • Majem M, Juan O, Insa A, et al. CLINICAL GUIDES IN ON-COLOGY SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). 2094;21:3-17. doi:10.1007/s12094-018-1978-1
  • Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg [Internet]. 2011 Jul;128(1):305-10. Disponible en: /pmc/articles/PMC3124652/?report=abstract
Fuente de los datos: Dialnet